fascioliasis
FDA approves Novartis’ Egaten for parasitic infection fascioliasis
February 14, 2019Sales and Marketing Egaten, FDA, Novartis, fascioliasis, pharma
The FDA has taken the decision to authorise the use of Novartis’ Egaten (triclabendazole) in patients older than six years …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
